Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine

Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D

Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.

80% of hypertensive women found to be obese: Study

48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs

Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants

Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

GSK to form consumer healthcare business ‘Haleon’

The proposed demerger is the most significant corporate change for GSK in the last 20 years

Mezzion Pharma receives clear FDA path forward for the approval of Udenafil for single ventricle heart disease